Revenue
2022
2023
2024
2025
Exozymes Inc. (EXOZ)
Price$6.85Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $70,069 | $0 |
| Research & development | $3.7M | $1.9M | $527,480 | $376,682 |
| Operating expenses | $9.7M | $5.9M | $1.9M | $1.3M |
| Operating income | −$9.7M | −$5.9M | −$1.8M | −$1.3M |
| Operating margin | — | — | −2,563.50% | — |
| EBITDA | −$9.4M | −$5.7M | −$1.6M | −$1.2M |
| EBITDA margin | — | — | −2,282.44% | — |
| Net income | −$9.2M | −$5.9M | −$2.0M | −$1.4M |
| Net profit margin | — | — | −2,909.12% | — |
| Basic EPSper basic share | -$1.09 | -$0.89 | -$0.33 | -$0.17 |
| Diluted EPSper diluted share | -$1.09 | -$0.89 | -$0.33 | -$0.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 9, 2026Form 4 | Korman Tyler PazChief Scientific Officer | SellCOMMON STOCK | 750 | $10.53 | $7.9K | 729.1K |
| Apr 8, 2026Form 4 | Korman Tyler PazChief Scientific Officer | SellCOMMON STOCK | 750 | $10.04 | $7.5K | 729.9K |
| Jul 2, 2025Form 4 | Heltzen MichaelChief Executive Officer | BuyCommon Stock | 1.0K | $10.22 | $10.6K | 10.6K |
| Jan 17, 2025Form 4 | Heltzen MichaelChief Executive Officer | BuyCommon Stock | 1.8K | $10.78 | $19.0K | 3.9K |
| Jan 16, 2025Form 4 | Heltzen MichaelChief Executive Officer | BuyCommon Stock | 121 | $10.72 | $1.3K | 2.1K |
Community posts
eXoZymes selects Curia to scale up its NCT manufacturing process
eXoZymes ($EXOZ) entered an agreement with contract manufacturer Curia to transfer and scale its NCT production process. Work will take place at Curia facilities in Spain and Italy, covering enzyme production, the cell-free reaction and pro ...